Paracrine utilizes an autologous mixed population of adipose-derived regenerative cells that contribute to multiple cell lineages and mechanisms of action to treat complex conditions. This unique heterogeneous cell therapy addresses critical underlying pathologic conditions. The company’s Celution System can process these regenerative cells in about an hour right at the bedside . . .